RSS-Feed abonnieren
DOI: 10.1055/a-2087-3003
Risk Factors for Postdischarge Major Thromboembolism and Mortality in Hospitalized Patients with COVID-19 with Cardiovascular Comorbidities: Insights from the CORE-19 Registry
Funding The CORE-19 registry was funded in part by the Broxmeyer Fellowship in Clinical Thrombosis, Janssen Pharmaceuticals, and a scholarship provided by the Hellenic Medical Society of New York (HMSNY). This work was also supported by grant R24AG064191 from the National Institute on Aging of the National Institutes of Health. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. The views expressed in this article are those of the authors and do not represent the views of the National Institutes of Health, the United States Department of Health and Human Services, or any other government entity.
Abstract
Background Coronavirus disease 2019 (COVID-19) is associated with venous and arterial thromboembolism (VTE and ATE) and all-cause mortality (ACM) in hospitalized patients. High-quality data are needed on postdischarge outcomes in patients with cardiovascular disease.
Objectives To analyze outcomes and identify risk factors for ATE, VTE, and ACM in a high-risk subgroup of hospitalized COVID-19 patients with baseline cardiovascular disease.
Methods We investigated postdischarge rates and associated risk factors of ATE, VTE, and ACM in 608 hospitalized COVID-19 patients with coronary artery disease, carotid artery stenosis (CAS), peripheral arterial disease (PAD), or ischemic stroke.
Results Through 90 days postdischarge, outcome rates were: ATE 27.3% (10.2% myocardial infarction, 10.1% ischemic stroke, 13.2% systemic embolism, 12.7% major adverse limb event); VTE 6.9% (4.1% deep vein thrombosis, 3.6% pulmonary embolism); composite of ATE, VTE, or ACM 35.2% (214/608). Multivariate analysis showed significant association between this composite endpoint and age >75 years (odds ratio [OR]: 1.90, 95% confidence interval [CI]: 1.22–2.94, p = 0.004), PAD (OR: 3.23, 95% CI: 1.80–5.81, p ≤ 0.0001), CAS (OR: 1.74, 95% CI: 1.11–2.75, p = 0.017), congestive heart failure (CHF) (OR: 1.84, 95% CI: 1.02–3.35, p = 0.044), previous VTE (OR: 3.08, 95% CI: 1.75–5.42, p < 0.0001), and intensive care unit (ICU) admission (OR: 2.93, 95% CI: 1.81–4.75, p < 0.0001).
Conclusion COVID-19 inpatients with cardiovascular disease experience high rates of ATE, VTE, or ACM through 90 days postdischarge. Age >75 years, PAD, CAS, CHF, previous VTE, and ICU admission are independent risk factors.
Keywords
COVID-19 - arterial thromboembolism - venous thromboembolism - anticoagulation - postdischarge outcomesNote
“High rates and risk factors of #ATE, #VTE, and all-cause mortality through three months post-discharge in a high risk #COVID-19 population with cardiovascular comorbidities: Insights from the CORE-19 registry.”
Authors' Contribution
D.G. and A.C.S. conceived and designed the study; D.G., M.G., H.R., C.P.S., M.L.L., S.N., J.T., M.Q., S.S., J.Y., M.M., E.A., and A.C.S. acquired, analyzed, or interpreted data; H.R.,C.P.S, M.L.L, J.T., M.Q., S.S., and J.Y. performed statistical analysis; A.C.S., M.M., J.Y., and E.A. supervised the study; D.G., A.C.S., and M.G. drafted the manuscript; D.G., H.R., C.P.S, M.L.L, J.T., M.Q., S.S., and J.Y. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis; and all authors approved the final version of the manuscript.
Publikationsverlauf
Eingereicht: 17. März 2023
Angenommen: 03. Mai 2023
Accepted Manuscript online:
05. Mai 2023
Artikel online veröffentlicht:
01. Juni 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany